Nykode Therapeutics (NYKD) ASIT 2025 presentation summary

Strategic positioning and pipeline

• Focus on APC-targeted immunotherapies for oncology and autoimmune diseases, leveraging a differentiated platform for tailored immune responses.

• Broad clinical pipeline includes assets for cervical cancer, head & neck cancer, solid tumors, infectious diseases, and autoimmune indications.

• Lead asset VB10.16 targets high unmet needs in HPV16+ cancers; individualized cancer vaccines in basket trials.

• Strategic multiprogram collaboration with Regeneron covers oncology and infectious diseases.

• Strong financial position with $115.4m in cash as of December 31, 2024.

Technology and platform innovation

• Modular vaccine design incorporates targeting, antigen, and modulatory units for antigen-specific immune tolerance.

• Platform enables antigen-specific downregulation of immune responses, affecting all major immune system components.

• Flexibility to incorporate various antigens and AI-driven solutions for optimal vaccine design.

• In-house AI/ML capabilities support personalized vaccine design, validated in clinical trials and across multiple indications.

• Several patent applications filed for modular and targeting concepts.

Mechanism of action and preclinical data

• Tolerance induction achieved by targeting disease-causing epitopes to tolerogenic APCs, leading to regulatory T cell activation and suppression of disease-specific effector cells.

• Published data show differential immune responses based on targeting distinct APC receptors.

• APC targeting is essential for effective disease protection and durable therapeutic effects in preclinical EAE and T1D models.

• Dose-dependent reduction in disease-associated cytokine release and autoantibody levels demonstrated.

• Early and late therapeutic administration of targeted vaccines significantly ameliorates disease progression in EAE and NOD diabetes models.